AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06051019 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance training
Description: Balance training: 15 daily sessions (5 sessions per week), each lasting approximately 90 minutes. Treatments will be performed with a physical therapist and will consist of the following exercises: 1) standing with feet together, 2) standing with closed eyes, 3) standing on unstable surfaces, 4) standing while performing upper limbs movements; 5) standing while performing head rotations; 6) walking on a treadmill at alternating speeds; 7) leg press and chest press exercises for training trunk balance during ballistic movements of the upper and lower limbs. These constituents of balance training can be combined in the same task according to the participant's ability.
Study NCT03982784 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: single-injection TQLB(transmuscular quadratus lumborum block)
Description: Inject 0.6ml/kg local anesthetics in between quadratus lumborum and psoas major under ultrasound guidance
Study NCT01396148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate dose escalation
Description: sunitinib starting dose will be 15mg/m\^2 daily on a 4 weeks on/2 weeks off schedule (Schedule 4/2).
Study NCT01396148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: sunitinib 50mg daily on Schedule 4/2
Study NCT03910842 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-TriCAR-T/SILK
Description: A conditioning chemotherapy regimen of fludarabine and cyclophosphamide may be administered, followed by a single infusion of CD19-TriCAR-T cells or 4 repeat infusions of CD19-TriCAR-SILK cells.
Study NCT02834494 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Biopsy
Description: Optional biopsy of breast tumor under neoadjuvant chemotherapy after the course 2 of anthracycline.
Study NCT02090218 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: I-Gel
Description: I-Gel supraglottic airway device
Study NCT03982784 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine given as IPCA(intravenous patient controlled analgesia)
Description: PCIA was initiated using a pump set to deliver boluses of 1.5-2 mg of morphine with a 5-minute lockout interval and no background infusion. The maximal permitted dosage of morphine was set at 8 mg/h.
Study NCT03982784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine given as IPCA(intravenous patient controlled analgesia)
Description: PCIA was initiated using a pump set to deliver boluses of 1.5-2 mg of morphine with a 5-minute lockout interval and no background infusion. The maximal permitted dosage of morphine was set at 8 mg/h.
Study NCT02258568 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking abstinence counseling
Description: Telephone smoking abstinence counseling based on motivational interviewing concepts
Study NCT01536028 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: biphasic insulin aspart 30
Description: A single dose administrated subcutaneously (s.c., under the skin) on four separate dosing visits in random order with a washout of 1-2 weeks in-between
Study NCT01536028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 30
Description: A single dose administrated subcutaneously (s.c., under the skin) on four separate dosing visits in random order with a washout of 1-2 weeks in-between
Study NCT01536028 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: biphasic insulin aspart 50
Description: A single dose administrated subcutaneously (s.c., under the skin) on four separate dosing visits in random order with a washout of 1-2 weeks in-between
Study NCT01536028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 50
Description: A single dose administrated subcutaneously (s.c., under the skin) on four separate dosing visits in random order with a washout of 1-2 weeks in-between
Study NCT02090218 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LTS, ETI or current airway management practice
Description: Laryngeal tube, endotracheal tube, bag-mask-ventilation
Study NCT04347902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Lipid Emulsion
Description: Various types of intravenous lipids
Study NCT01536028 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: biphasic insulin aspart 70
Description: A single dose administrated subcutaneously (s.c., under the skin) on four separate dosing visits in random order with a washout of 1-2 weeks in-between
Study NCT01536028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 70
Description: A single dose administrated subcutaneously (s.c., under the skin) on four separate dosing visits in random order with a washout of 1-2 weeks in-between
Study NCT01536028 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: A single dose administrated subcutaneously (s.c., under the skin) on four separate dosing visits in random order with a washout of 1-2 weeks in-between
Study NCT01536028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: A single dose administrated subcutaneously (s.c., under the skin) on four separate dosing visits in random order with a washout of 1-2 weeks in-between
Study NCT04347902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Lipid Emulsion
Description: Various types of intravenous lipids
Study NCT01121237 — intervention group
Intervention type: DRUG
Intervention: Recombinant human erythropoietin alfa (biosimilar)
Description: Recombinant human erythropoietin alfa (biosimilar) commercially available as prescribed per treating physician
Study NCT03214965 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Facebook group
Description: A closed facebook group used to deliver multimedia content specifically produced to inform the participants about chronic kidney disease, kidney transplantation and related topics. This group is also used to share doubts and life experiences among participants and the interdisciplinary team.
Study NCT04631198 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thoracoabdominal rebalancing
Description: the patients selected for the intervention group will be submitted to the handling of thoracoabdominal rebalancing as abdominal supports and / or in the ileo-costal space, inspiratory help, scapular waist release, thoracic swing, pectoralis major muscle release and deltoid together with aspiration if necessary.
Study NCT03950115 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intense Pulsed Light (IPL)
Description: IPL therapy will be performed with the M22® (Lumenis, Dreieich, Germany). IPL treatment is going to be administered to the skin below the lower eyelid. Before treatment, the eyes will be protected with opaque goggles. Ultrasound gel is going to be applied to the patient's face from tragus to tragus including the nose in order to conduct the light, help to spread the energy evenly, and provide a degree of protection. The intensity of the IPL treatment will range from 9.8J/cm2 to 13J/cm2 according to Fitzpatrick Skin Type Grading.
Study NCT03398174 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor Control Exercise
Description: Exercise aiming at improving function of specific muscles of the lumbopelvic region and the control of posture and movement.~In addition, participants will perform stretching exercises aiming at targeting the postural muscles and connective tissue around the lower back, pelvis and lower limb that tend to get shortened in chronic LBP, and they will be advised to perform aerobic exercise in the form of overground walking at desirable speed at home.
Study NCT03714217 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telenutrition Counseling
Description: A registered dietitian nutritionist will contact each participant twice a month for 3 months to provide nutrition counseling via iPad FaceTime.
Study NCT02941978 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interview
Description: Patients assigned to the intervention group receive additional medical consultation aiming to boost optimal uptake of the anticoagulation regimen prescribed. Initially (i.e., at hospital discharge), this includes a physician-patient interactive session and provision of an educational leaflet. The leaflet is designed in a culturally and linguistically conceivable template in Greek language. It uses simple terms together with both written and pictorial materials. Patients in the intervention group will also undergo short telephonic sessions at 1 week, 2 months, 6 months and 12 months following hospital discharge
Study NCT02941978 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Patients assigned to the control group receive usual treatment, corresponding to standard practice and management of hospitalized patients with AF. For both patient-groups, the choice of OAC agent and any other background therapy is left to the discretion of the treating physician.
Study NCT03052725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: reslizumab
Description: Reslizumab was provided in a pre-filled syringe.
Study NCT03398174 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Education
Description: Patient education to enable patients to better understand their pain, change any unhelpful beliefs about LBP, and integrate self-management and active coping strategies that deals with fear avoidance behavior and catastrophic thought.~In addition, participants will perform stretching exercises aiming at targeting the postural muscles and connective tissue around the lower back, pelvis and lower limb that tend to get shortened in chronic LBP, and they will be advised to perform aerobic exercise in the form of overground walking at desirable speed at home.
Study NCT02148601 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Study NCT02148601 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Antibiotic Therapy
Study NCT02148601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin (before randomization)
Description: Vancomycin will be administered in all patients for 5 days before randomization. Then, patients will be randomized in FMT Group or Standard Antibiotic therapy Group. Patients in the FMT Group will stop vancomycin 24 hours before the fecal microbiota transplantation. Patients in the Standard Antibiotic Therapy Group will continue vancomycin.
Study NCT02148601 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin (before randomization)
Description: Vancomycin will be administered in all patients for 5 days before randomization. Then, patients will be randomized in FMT Group or Standard Antibiotic therapy Group. Patients in the FMT Group will stop vancomycin 24 hours before the fecal microbiota transplantation. Patients in the Standard Antibiotic Therapy Group will continue vancomycin.
Study NCT03143894 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: Transcranial direct current stimulation (tDCS) is a safe, portable, non-invasive form TDCS is a form of non-invasive electrical brain stimulation using low amplitude direct current to facilitate neuronal transmission beneath scalp electrodes.
Study NCT03143894 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: Transcranial direct current stimulation (tDCS) is a safe, portable, non-invasive form TDCS is a form of non-invasive electrical brain stimulation using low amplitude direct current to facilitate neuronal transmission beneath scalp electrodes.
Study NCT03737396 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Self-administered electronic health screening
Description: Health assessment using an electronic device
Study NCT03143894 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham tDCS
Description: Sham Transcranial direct current stimulation (tDCS)..
Study NCT03143894 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Sham Transcranial direct current stimulation (tDCS)..
Study NCT02353104 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Onion-Pumpkin Extract
Study NCT00808366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Keratolytic/Antifungal
Description: Intial treatment with RV4104A ointment for 3 weeks. Subsequent topical antifungal treatment with bifonazole cream for 8 weeks.
Study NCT00808366 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Keratolytic/Antifungal
Description: Initial treatment with bifonazole-urea ointment for 3 weeks. Subsequent topical antifungal treatment with bifonazole cream for 8 weeks.
Study NCT02454998 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: orthodontic treatment
Description: Braces on the upper dental arch previous to surgical alveolar bone grafting. the goal is optimizing the structure of dental-alveolar structure.
Study NCT02067338 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1 mg morphine soak in epidural oxidized cellulose
Description: During posterior lumbar spinal surgery , patients received 1 mg morphine-soaked in epidural oxidized cellulose.
Study NCT02067338 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: During posterior lumbar spinal surgery , patients received NSS -soaked in epidural oxidized cellulose.
Study NCT00682162 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: The treatment consisted of 5 sessions, all patients completed a recovery time after treatment of 30 min duration. The sessions were administered over a period of 5 weeks (one session per week). The acupuncture treatment was semi-standardised. It consisted of a basic pool of 6 body acupuncture points. Five additional acupuncture body points together with auricular points formed an individual pool. After needle insertion, the needle was manipulated until the subject obtained the de-Qi response (a deep aching or full feeling at the needle, \[22\]). After obtaining the de-Qi response, there was no further manipulation of the needle. Each session lasted 20 minutes.
Study NCT00682162 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-laser acupuncture
Description: The sham-laser acupuncture treatment consisted of 5 sessions, all patients completed a recovery time after treatment of 30 min duration. The sessions were administered over a period of 5 weeks (one session per week). Sham-laser acupuncture was applied at the same points as the acupuncture treatment. A deactivated laser pen (Seirin, 3B Scientific GmbH, Hamburg, Germany) that could only beam normal red light rather than laser was used. The total number of acupuncture points utilized was equal to the acupuncture group. Every point was treated for 30 sec with the total treatment time of 20 minutes.
Study NCT01876797 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ticagrelor/prasugrel
Study NCT01953263 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous Muscle Fiber Fragments
Description: Autologous muscle fiber fragments administered via a single direct injection into the bladder neck sphincter region
Study NCT02039492 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sympathetic Renal Denervation
Study NCT02039492 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment with aldactone
Study NCT01024634 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Endurance Exercise
Description: 8 weeks of Endurance exercise training, 3-4 times per week, 45-60 minutes perr session
Study NCT04517812 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise-based games via the VirtualRehab platform
Description: A 12-week exercise-based home rehabilitation intervention delivered via the VirtualRehab platform. A personalised exercise-based rehabilitation plan will be created for each participant.
Study NCT03937011 — intervention group
Intervention type: DEVICE
Intervention: Robotic Suturing of gastric sleeve oversew and vaginal cuff closure
Description: 1. Robotic Bariatric Sleeve gastrectomy~2. Robotic Hysterectomy with or without oophorectomy;
Study NCT00694785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC1779
Description: Initial stepwise infusion of 0.14 mg/kg given over 60 minutes and subsequent continuous infusion of an additional 1.7 mg/kg given over the remaining 72 hours at a rate of 0.0004 mg/kg/min.~Group NT3
Study NCT00694785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC1779
Description: Initial stepwise infusion of 0.14 mg/kg given over 60 minutes and subsequent continuous infusion of an additional 1.3 mg/kg given over the next 72 hours.~Group T3
Study NCT00694785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC1779
Description: Initial stepwise infusion of 0.28 mg/kg given over 60 minutes and subsequent continuous infusion of an additional 3.8 mg/kg given over the remaining 72 hours at a rate of 0.0009 mg/kg/min.~Group NT6
Study NCT00694785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC1779
Description: Initial stepwise infusion of 0.28 mg/kg given over 60 minutes and subsequent continuous infusion of an additional 3.0 mg/kg given over the remaining 72 hours.~Group T6
Study NCT02270957 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept
Study NCT02286752 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: for reversal of neuromuscular block: 0,05 mg kg-1 neostigmine + 0,025 mg kg-1 atropine
Study NCT01638975 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Response Inhibition Training Program
Description: This is a computerized cognitive retraining program consisting of 8 sessions delivered over a 4-week period.
Study NCT02270957 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00048555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDEC-114
Description: Dose Group 1 - 125 mg/m2 x 4 infusions \& 375 mg/m2 Rituxan x 4 infusions Dose Group 2 - 250 mg/m2 x 4 infusions \& 375 mg/m2 Rituxan x 4 infusions Dose Group 3 - 375 mg/m2 x 4 infusions \& 375 mg/m2 Rituxan x 4 infusions Dose Group 4 - 500 mg/m2 x 4 infusions \& 375 mg/m2 Rituxan x 4 infusions
Study NCT03516994 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Respecting Choices First Steps
Description: Advance Care Planning Approach
Study NCT03516994 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Five Wishes Form
Description: Advance Care Planning Approach
Study NCT03752294 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabigatran
Description: At the end of a 9-month randomized-control, double-blind treatment all study participants will cross-over to the 12-month open-label phase with a 3-month non-treatment follow-up.
Study NCT03752294 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Cap
Description: At the end of a 9-month randomized-control, double-blind treatment all study participants will cross-over to the 12-month open-label phase with a 3-month non-treatment follow-up
Study NCT04554667 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Heavy Lifting Strength Training
Study NCT05062382 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Complementary feeding intervention
Description: The study promoted eggs.~GAIN provided training to egg farmers to increase their egg production and marketing, helped increase mother's access to eggs by making them more available in local kiosks and getting retailers to display promotional messages around eggs, conducted sensitization workshops with retailers to increase egg purchases, and employed a demand creation campaign.
Study NCT01283360 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: HEC Placebo Gel
Description: The HEC universal placebo gel for Stage 2 will be supplied by CONRAD (Arlington, VA, USA). Under direction from CONRAD, DPT Laboratories will manufacture the HEC placebo gel and analyze/release the gels under cGMP. DPT Laboratories will fill the applicators with HEC placebo gel to create pre-filled applicators and package each applicator and plunger in a wrapper. Each pre-filled applicator will contain and deliver a dose of approximately 4 mL of HEC gel.
Study NCT01283360 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir 1% Gel
Description: Tenofovir 1% gel will be supplied by CONRAD (Arlington, VA, USA). Under direction from CONRAD, DPT Laboratories will manufacture the tenofovir 1% gel and analyze/release the gels under cGMP. DPT Laboratories will fill the applicators designed for vaginal use with tenofovir 1% gel to create pre-filled applicators and package each applicator and plunger in a wrapper. Each pre-filled applicator will contain and deliver a dose of approximately 4 mL of tenofovir 1% gel (equal to 4.4 g).
Study NCT00743340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine
Description: 6 mg/kg capsule once daily, up to a maximum dose of 200 mg once daily, or 10 mg/mL oral solution once daily, up to a maximum of 240 mg once daily
Study NCT01929460 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ciprofloxacin
Description: ciprofloxacin oral capsule (one capsule twice a day for 3 days)
Study NCT01929460 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for ciprofloxacin)
Description: oral placebo capsule (one capsule twice a day for 3 days)
Study NCT00127660 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Menu: calories=yes, value pricing=no
Study NCT00127660 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Menu: calories=yes, value pricing = yes
Study NCT00127660 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Menu: calories=no, value pricing = no